You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Computational tools to analyze SNP data from patients with mental illness

    SBC: PARTEK, INC.            Topic: 101

    DESCRIPTION provided by applicant The broad long term objective of the proposed research is to develop and market a commercial software product that can be used to facilitate the analysis of genetic changes in order to elucidate chromosomal abnormalities that underlie diseases such as autism spectrum disorder bipolar disorder and schizophrenia Recent technological advances allow samples of ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    SBC: VASCULOX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Monodispersed magnetic nanoparticles for improved diagnostic imaging. Phase II: S

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic cancer (PC) is the fourth leading cause of death from cancer in the US. Treatment options for this disease are extremely limited and prognosis is poor. At present, less than 6% of PC patients are alive afterfive years with an average survival time following diagnosis of 4-6 months, which is among the lowest for all cancers. It is clear that new thera ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: APT THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Bone metastasis is common in patients with advanced breast, prostate, and lung cancers as these tumors have a remarkable ability to metastasize to bone. Two-thirds of patients with metastatic bone cancer experience severe pain which is usually described as dull in character, constant in presentation, and gradually increasing in intensity with time. Bone cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. An Automated Platform for High-throughput Network Electrophysiology

    SBC: CALISTA THERAPEUTICS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Mesodissection Device Phase II

    SBC: MEDSOCKET OF MISSOURI, INC.            Topic: NLM

    DESCRIPTION (provided by applicant): Physicians, no matter how well prepared, generate an average of two clinical questions per every three patient encounters. In 2009, the 1.3 billion visits to physicians' offices, hospital outpatient departments, and hospital emergency departments produced roughly 867 million questions. Answers to such questions likely exist, typically spread among several ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Developing an Improved Electrocompetent E. coli Host

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NCATS

    DESCRIPTION (provided by applicant): Chronic musculoskeletal pain creates a significant public health burden. Veterans are disproportionately affected by chronic musculoskeletal pain, and in particular, chronic low back pain (CLBP). The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), and all three conditions (Post-deployment Multi-symptom Disorder (PM ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Anti-CD47 mAb Therapy to Improve Kidney Transplantation

    SBC: VASCULOX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease. In spite of many improvements in organ procurement, transplant procedures and immune suppression, the damage done by ischemia-reperfusion injury (IRI) remains problematic, leading to primary graft nonfunctional, delayed graft function and graft failure. The critical shortage of ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Expediting the Production of High Value, Standardized, and Transparent Data

    SBC: MJ Datacorp, Ltd.            Topic: NCATS

    DESCRIPTION (provided by applicant): Researchers and contractors are under increasing pressure to produce rapid turnaround times for data releases and publications. Inadequate data management is a common threat to good research and impedes the quick release of high value data. Despite its importance, many organizations do not have standardized data management practices that allow them to prepare h ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government